Predictors of efficacy of allergen immunotherapy in children with seasonal allergic rhinoconjunctivitis and pollen-food allergy syndrom

Abstract

Objective of the research. To study predictors of efficacy of AIT in relation to the symptoms of seasonal ARC and PFAS in children with different IgE profiles. Materials and methods. Open prospective observational study of 161 patients aged 5 to 17 years with clinical symptoms of ARC (the annual escalation in April-May, duration of the disease is not less than 2 years, the need for symptomatic therapy in the flowering season of cause-significant plants) and PFAS for products of plant origin. The examination included skin testing, as well as sIgE determination of birch pollen allergen extract, cross-food allergens of plant origin (apple, pear, cherry, peach, carrot) and recombinant birch pollen allergens allergens (rBet v 1, rBet v 2, rBet v 4, rBet v 6) on the automatic analyzer ImmunoCAP250. All patients received two courses of AIT, sublingual administration. Assessment of efficacy was performed using the modified scheme A.D. Ado and diagnostic introduction earlier unbearable product. Conclusion. Monosensitization to rBet v 1 is a clinical and laboratory marker of the high efficacy of AIT in children with seasonal ARC and PFAS. Conclusion. Monosensitization to rBet v 1 is a clinical and laboratory marker of the high efficacy of ACIT in children with pollinosis and cross-PAS. Daily high-dose immunotherapy with standardized extract of birch pollen allergen has a good therapeutic effect, including in relation to the manifestations ofPFAS.